Targeting Necrosis: Elastase-like Protease Inhibitors Curtail Necrotic Cell Death Both In Vitro and in Three In Vivo Disease Models

J Med Chem. 2021 Feb 11;64(3):1510-1523. doi: 10.1021/acs.jmedchem.0c01683. Epub 2021 Jan 31.

Abstract

Necrosis is the main mode of cell death, which leads to multiple clinical conditions affecting hundreds of millions of people worldwide. Its molecular mechanisms are poorly understood, hampering therapeutics development. Here, we identify key proteolytic activities essential for necrosis using various biochemical approaches, enzymatic assays, medicinal chemistry, and siRNA library screening. These findings provide strategies to treat and prevent necrosis, including known medicines used for other indications, siRNAs, and establish a platform for the design of new inhibitory molecules. Indeed, inhibitors of these pathways demonstrated protective activity in vitro and in vivo in animal models of traumatic brain injury, acute myocardial infarction, and drug-induced liver toxicity. Consequently, this study may pave the way for the development of novel therapies for the treatment, inhibition, or prevention of a large number of hitherto untreatable diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Injuries, Traumatic / drug therapy
  • Brain Injuries, Traumatic / pathology
  • Cell Death / drug effects
  • Chemical and Drug Induced Liver Injury / drug therapy
  • High-Throughput Screening Assays
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / pathology
  • Necroptosis / drug effects*
  • Necrosis / prevention & control*
  • Pancreatic Elastase / antagonists & inhibitors*
  • Protease Inhibitors / chemical synthesis*
  • Protease Inhibitors / pharmacology*
  • RNA, Small Interfering
  • U937 Cells

Substances

  • Protease Inhibitors
  • RNA, Small Interfering
  • Pancreatic Elastase